Trinity Delta Lighthouse: Arecor Therapeutics
Trinity Delta view: Arecor continues to advance across its multi-faceted business as it builds a self-sustaining biopharma company. Demonstrable clinical progress with its Diabetes and Specialty Hospital pipeline and growing revenue potential from existing (and future) partnerships as well as from its commercial arm, Tetris Pharma, all contribute momentum. Data, regulatory decisions, and business development activity are expected in H223; the latter demonstrating the applicability of the proprietary Arestat platforms in developing novel and differentiated formulations of existing drugs with enhanced properties. We value Arecor, using conservative assumptions, at £176m, or 575p per share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.